Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SEEL

SEEL - Seelos Therapeutics Inc Stock Price, Fair Value and News

1.89USD-0.45 (-19.23%)Market Closed

Market Summary

SEEL
USD1.89-0.45
Market Closed
-19.23%

SEEL Stock Price

View Fullscreen

SEEL RSI Chart

SEEL Valuation

Market Cap

38.9M

Price/Earnings (Trailing)

-5.46

Price/Sales (Trailing)

19.69

EV/EBITDA

-0.16

Price/Free Cashflow

-2.13

SEEL Price/Sales (Trailing)

SEEL Profitability

EBT Margin

-1130.51%

Return on Equity

21.5%

Return on Assets

-197.07%

Free Cashflow Yield

-46.84%

SEEL Fundamentals

SEEL Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-28.34%

Rev. Growth (Qtr)

-11.33%

SEEL Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

80.17%

Earnings Growth (Qtr)

89.53%

Breaking Down SEEL Revenue

52 Week Range

0.152.38
(Low)(High)

Last 7 days

742.9%

Last 30 days

505.1%

Last 90 days

184.3%

Trailing 12 Months

143.3%

How does SEEL drawdown profile look like?

SEEL Financial Health

Current Ratio

0.1

Debt/Equity

1e-4

Debt/Cashflow

-4.6K

SEEL Investor Care

Shares Dilution (1Y)

309.05%

Diluted EPS (TTM)

-7.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0M000
2023910.0K1.2M1.6M2.2M
2022120.0K0127.0K128.0K
202137.0K59.0K94.0K113.0K
2020392.0K409.0K38.0K45.0K
20194.4M3.1M1.7M375.0K
20165.0M5.0M8.0M5.8M
20159.7M4.7M4.1M4.8M
201407.0M7.7M9.6M
20138.2M9.4M4.5M2.5M
20124.7M5.8M6.9M7.9M
20115.2M5.3M5.0M3.6M
201003.6M4.3M5.0M
20090003.0M

Tracking the Latest Insider Buys and Sells of Seelos Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 29, 2024
golembiewski michael joseph
acquired
457
1.097
417
chief financial officer
Dec 01, 2023
mehra raj
bought
99,999
1.32
75,757
see remarks
Nov 30, 2023
golembiewski michael joseph
bought
100,222
1.2075
83,000
chief financial officer
Aug 31, 2023
golembiewski michael joseph
acquired
7,725
0.618
12,500
chief financial officer
Feb 28, 2023
golembiewski michael joseph
acquired
8,400
0.672
12,500
chief financial officer
Jun 01, 2022
o'connor daniel j.
bought
9,788
0.6118
16,000
-
May 26, 2022
dalesandro margaret
bought
20,965
0.599
35,000
-
Mar 31, 2022
mehra raj
bought
56,840
0.8526
66,667
see remarks
Feb 28, 2022
golembiewski michael joseph
acquired
11,262
0.901
12,500
chief financial officer
Feb 13, 2020
mehra raj
bought
99,999
0.75
133,333
see remarks

1–10 of 11

Which funds bought or sold SEEL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
Tower Research Capital LLC (TRC)
added
99.19
-1,123
6,216
-%
May 15, 2024
GENDELL JEFFREY L
added
284
98,375
253,519
0.01%
May 15, 2024
Royal Bank of Canada
sold off
-100
-
-
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-10,346
7,652
-%
May 15, 2024
MORGAN STANLEY
added
79.67
-23,023
74,504
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-0.03
-3,004
2,220
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-48.17
-27,359
7,733
-%
May 15, 2024
LM Advisors LLC
sold off
-100
-115
-
-%
May 15, 2024
Vermillion & White Wealth Management Group, LLC
new
-
588
588
-%
May 15, 2024
FIRST MANHATTAN CO. LLC.
unchanged
-
-298
219
-%

1–10 of 44

Are Funds Buying or Selling SEEL?

Are funds buying SEEL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SEEL
No. of Funds

Unveiling Seelos Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 06, 2024
lind global fund ii lp
9.9%
1,410,800
SC 13G
Feb 09, 2023
vanguard group inc
4.68%
5,016,741
SC 13G/A
Jul 08, 2022
blackrock inc.
1.7%
1,779,835
SC 13G
Feb 04, 2022
blackrock inc.
6.4%
6,563,054
SC 13G
Feb 10, 2021
vanguard group inc
5.24%
2,799,854
SC 13G
Jan 15, 2021
ligand pharmaceuticals inc
4.1%
2,224,000
SC 13G/A
Jan 11, 2021
phoenixus ag
0%
0
SC 13G/A
Feb 14, 2020
altium capital management lp
0.00%
0
SC 13G/A
Feb 14, 2020
armistice capital, llc
0%
0
SC 13G/A
Feb 12, 2020
ligand pharmaceuticals inc
8.1%
2,224,000
SC 13G/A

Recent SEC filings of Seelos Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 16, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report
May 14, 2024
8-K
Current Report
May 03, 2024
8-K
Current Report
Apr 29, 2024
10-K/A
Annual Report
Mar 28, 2024
8-K
Current Report
Mar 19, 2024
8-K
Current Report
Mar 15, 2024
EFFECT
EFFECT
Mar 15, 2024
424B3
Prospectus Filed
Mar 12, 2024
CORRESP
CORRESP

Peers (Alternatives to Seelos Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
27.86% 5.69%
-8.52
7.43
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.08% -21.73%
-57.61
9.55
75.20% 68.82%
14.6B
2.5B
-15.33% -16.61%
71.11
5.91
13.74% 186.89%
12.8B
3.8B
6.86% -11.90%
17.13
3.39
8.58% 129.81%
MID-CAP
5.8B
107.9M
23.06% 120.60%
-10.63
48.09
54.84% -28.31%
5.1B
524.1M
-18.99% -52.96%
-12.22
9.73
394.93% 39.61%
3.7B
251.0M
12.53% -1.35%
-12.4
14.64
73.58% -86.73%
3.1B
240.7M
5.66% -32.59%
-6.6
12.77
-1.03% -213.43%
2.5B
813.8M
-13.11% -34.57%
-1.4K
3.01
56.43% 98.83%
SMALL-CAP
2.0B
996.6M
260.65% 85.68%
-5.07
2.03
-26.66% 65.49%
1.9B
411.3M
5.34% 30.65%
29.69
4.7
60.38% -34.49%
489.5M
881.7K
11.38% 343.80%
-14.5
481.06
-77.61% 33.36%
330.9M
4.9M
32.47% 47.80%
-2.65
67.99
-54.97% 48.23%
15.7M
2.1M
-6.67% 89.09%
-0.68
7.61
-13.45% 69.54%

Seelos Therapeutics Inc News

Latest updates
PR Newswire • 16 hours ago
Investing.com • 14 May 2024 • 05:55 pm
PR Newswire • 14 May 2024 • 03:45 pm
MarketBeat • 11 May 2024 • 03:12 pm

Seelos Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12016Q4
Revenue-11.3%57965340633680840.0036.0026.0026.0039.0029.0019.007.004.007.0027.00-375369362356
Gross Profit---------------------282
Operating Expenses-23.4%6,6348,66413,00911,2899,74018,25717,41014,01027,37410,9106,77316,6125,8454,0853,3205,50910,3304,0563,39412,342-
  S&GA Expenses-100.0%-2,7462,9872,7804,0722,7522,6604,0017,8282,2272,4652,5002,0132,0701,8761,8161,1321,4151,6903,322-
  R&D Expenses-40.4%3,5255,91810,0228,5095,66821,78314,75010,009-8,6834,30814,1123,8322,0151,4443,693-4,6032,641100100-
EBITDA Margin-10.7%-11.16*-10.08*-13.97*-18.25*-24.46*-173.92*-175.25*-180.50*-182.99*-218.42*-348.23*----------
Interest Expenses847.4%18019.0042.007.007.00-2.007.005.0020.005839901516.003.004.0013.005.006.005.00-
Income Taxes----------------------1.00
EBT Margin-11.6%-11.31*-10.13*-14.04*-18.29*-24.52*-174.35*-175.72*-185.97*-197.49*-237.41*-378.24*----------
Net Income89.5%-2,664-25,45010,49810,498-13,431-18,657-19,604-14,001-27,259-10,815-8,858-19,116-6,450-4,090-3,729-4,832-10,659-3,221-1,863-35,512-
Net Income Margin55.6%-3.61*-8.12*-6.98*-33.77*-80.18*-574.48*-646.74*-507.77*-584.50*-481.27*-652.78*----------
Free Cashflow-142.9%-4,642-1,911-5,749-5,904-10,348-13,090-11,074-17,045-18,339-10,510-8,894----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-33.3%4.005.006.0012.0024.0023.0041.0053.0071.0084.0081.0090.0041.0017.0010.008.0014.0011.0016.0010.0012.00
  Current Assets-34.3%4.005.006.0012.0024.0023.0041.0053.0071.0083.0081.0090.0041.0017.0010.008.0014.0011.0016.0010.0012.00
    Cash Equivalents-82.5%1.003.003.006.0014.0016.0031.0041.0062.0079.0077.0087.0039.0016.008.006.0013.0010.0015.0010.0011.00
Liabilities-5.7%37.0039.0037.0059.0044.0033.0033.0026.0025.0026.008.008.0017.0015.003.004.007.0011.006.005.009.00
  Current Liabilities-5.7%37.0039.0035.0056.0039.0025.0022.0015.0010.008.008.008.0013.007.003.004.007.0011.006.00--
  Long Term Debt------------0.003.007.00-------
    LT Debt, Current------------0.002.002.00-------
    LT Debt, Non Current------------0.003.007.00-------
Shareholder's Equity1.2%-33.10-33.51---20.66-10.618.0026.0046.0057.0073.0083.0025.003.007.004.007.00-10.005.003.00
  Retained Earnings-1.1%-255-252-247-257-228-214196177155-141-113-103-94.2875.00-68.71-64.62-60.89-56.06-45.40-42.18-40.32
  Additional Paid-In Capital1.4%22221921721020720420420320119818718611978.0075.0068.0068.0056.0056.0047.0043.00
Shares Outstanding55.8%15.0010.005.004.004.004.004.004.004.004.003.003.00---------
Float----145-70.00-----262---42.00-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-142.9%-4,642-1,911-5,749-5,904-10,348-13,090-11,074-20,395-17,045-18,339-10,510-8,894-11,252-3,329-4,180-6,981-6,423-5,118-2,910-3,337-7,940
  Share Based Compensation-0.9%9559649749881,0629079739612,2324,9008571,0377056976953413114,58513314438.00
Cashflow From Financing-6.6%2,1702,3232,490-2,3128,874-1,888334-12683.0020,24014357,40734,27710,9376,3801478,85064.008,4971,77319,190
  Buy Backs-----1,195----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SEEL Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue  
Total revenue$ 579$ 808
Revenue, Product and Service [Extensible Enumeration]us-gaap:GrantMemberus-gaap:GrantMember
Operating expense  
Research and development$ 3,525$ 5,668
General and administrative3,1094,072
Total operating expense6,6349,740
Loss from operations(6,055)(8,932)
Other income (expense)  
Interest income1067
Interest expense(23)(7)
Change in fair value of convertible notes(203)66
Loss on extinguishment of debt(1,493)(13)
Loss on issuance of common stock and warrants (4,301)
Change in fair value of warrant liabilities5,100(311)
Total other income (expense)3,391(4,499)
Net loss and comprehensive loss$ (2,664)$ (13,431)
Total loss per share basic (note 1)$ (0.20)$ (3.58)
Total loss per share-diluted (note 1)$ (0.20)$ (3.58)
Weighted-average common shares outstanding used for basic (note 1)13,007,5563,751,468
Weighted-average common shares outstanding used for diluted (note 1)13,007,5563,751,468

SEEL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash$ 524$ 2,996
Grant receivable968763
Prepaid expenses and other current assets2,0581,644
Total current assets3,5505,403
Operating lease right-of-use asset6215
Total assets3,6125,418
Current liabilities  
Accounts payable15,26816,403
Accrued expenses4,5242,516
Short-term portion of convertible notes payable, at fair value13,07514,213
Warrant liabilities, at fair value3,7875,781
Operating lease liability6215
Total current liabilities36,71638,928
Total liabilities36,71638,928
Commitments and contingencies (note 12)
Stockholders' equity (deficit)  
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value, 400,000,000 and 16,000,000 shares authorized, 15,256,268 and 9,794,594 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (note 1)1510
Additional paid-in-capital222,171219,106
Accumulated deficit(255,290)(252,626)
Total stockholders' equity (deficit)(33,104)(33,510)
Total liabilities and stockholders' equity (deficit)$ 3,612$ 5,418
SEEL
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://seelostherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES16

Seelos Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Seelos Therapeutics Inc? What does SEEL stand for in stocks?

SEEL is the stock ticker symbol of Seelos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seelos Therapeutics Inc (SEEL)?

As of Thu May 16 2024, market cap of Seelos Therapeutics Inc is 38.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SEEL stock?

You can check SEEL's fair value in chart for subscribers.

What is the fair value of SEEL stock?

You can check SEEL's fair value in chart for subscribers. The fair value of Seelos Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seelos Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SEEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seelos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SEEL is over valued or under valued. Whether Seelos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seelos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SEEL.

What is Seelos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SEEL's PE ratio (Price to Earnings) is -5.46 and Price to Sales (PS) ratio is 19.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SEEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seelos Therapeutics Inc's stock?

In the past 10 years, Seelos Therapeutics Inc has provided -0.429 (multiply by 100 for percentage) rate of return.